Metabotropic glutamate receptors in cancer

Yu, Lumeng J.; Wall, B.; Wangari-Talbot, Janet; Chen, Suzie

doi:10.1016/j.neuropharm.2016.02.011

Cited by 82 publications

(48 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Group III mGluR is involved in malignancy of a lot of cancers [47]. The implication of mGluR7 in tumor formation has yet to be characterized [46].…”

Section: Glutamate As a Growth Factor For Glioblastomamentioning

confidence: 99%

“…In addition, mutations and single nucleotide polymorphisms (SNPs) of GRM1 were described in prostate cancer [61] and eight somatic variations of GRM1 were identified in cancers, including lung adenocarcinoma [62]. Group II mGluR is also implicated in a variety of cancer types [47], including melanoma [63]. Both group I and II mGluR are involved in glioma progression and the action in vitro and in vivo of agonists and antagonists of these receptors will be reported in detail in this review.…”

Section: Glutamate As a Growth Factor For Glioblastomamentioning

confidence: 99%

See 1 more Smart Citation

Metabotropic glutamate receptors as a new therapeutic target for malignant gliomas

et al. 2017

View full text Add to dashboard Cite

Metabotropic glutamate receptors (mGluR) are predominantly involved in maintenance of cellular homeostasis of central nervous system. However, evidences have suggested other roles of mGluR in human tumors. Aberrant mGluR signaling has been shown to participate in transformation and maintenance of various cancer types, including malignant brain tumors. This review intends to summarize recent findings regarding the involvement of mGluR-mediated intracellular signaling pathways in progression, aggressiveness, and recurrence of malignant gliomas, mainly glioblastomas (GBM), highlighting the potential therapeutic applications of mGluR ligands. In addition to the growing number of studies reporting mGluR gene or protein expression in glioma samples (resections, lineages, and primary cultures), pharmacological blockade in vitro of mGluR1 and mGluR3 by selective ligands has been shown to be anti-proliferative and anti-migratory, decreasing activation of MAPK and PI3K pathways. In addition, mGluR3 antagonists promoted astroglial differentiation of GBM cells and also enabled cytotoxic action of temozolomide (TMZ). mGluR3-dependent TMZ toxicity was supported by increasing levels of MGMT transcripts through an intracellular signaling pathway that sequentially involves PI3K and NF-?B. Further, continuous pharmacological blockade of mGluR1 and mGluR3 have been shown to reduced growth of GBM tumor in two independent in vivo xenograft models. In parallel, low levels of mGluR3 mRNA in GBM resections may be a predictor for long survival rate of patients. Since several Phase I, II and III clinical trials are being performed using group I and II mGluR modulators, there is a strong scientifically-based rationale for testing mGluR antagonists as an adjuvant therapy for malignant brain tumors.

show abstract

“…Group III mGluR is involved in malignancy of a lot of cancers [47]. The implication of mGluR7 in tumor formation has yet to be characterized [46].…”

Section: Glutamate As a Growth Factor For Glioblastomamentioning

confidence: 99%

Section: Glutamate As a Growth Factor For Glioblastomamentioning

confidence: 99%

Metabotropic glutamate receptors as a new therapeutic target for malignant gliomas

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Consequently the activation of group II or III glutamate receptor membranes reduce cAMP formation [40,41]. Calcium and DAG activate protein kinase C, which, in turn, activates the MAPK and PI3K/AKT pathways which allow the upregulation of cell proliferation and anti-apoptosis signals [42]. Moreover; it has been observed that activated PI3K/AKT pathway functions in tumor cell by regulating; survival, angiogenesis and epithelial mesenchymal transition (EMT).…”

Section: Molecular Pathwaysmentioning

confidence: 99%

Melanoma from Molecular Pathways to Clinical Treatment: An Up to Date Review

Kosmıdis¹,

Baka²,

Sapalidis³

et al. 2017

J. Biomed

View full text Add to dashboard Cite

Skin cancer is divided to melanoma and non-melanoma. Melanoma occurs due to deregulation of melanocytes. Melanoma is frequent in Caucasian population. During the last decade there is an increase in melanoma and in many cases there is a diagnostic challenge. Moreover; choosing the right treatment is a challenge for many patients. Malignant melanoma is known to be a lethal disease due to its aggressive capacity for metastasis and resistance to therapy. In the last decade, considerable efforts have gone into development of an effective immunotherapy for treatment of melanoma. The combination of macrophage activation and other treatments such as immunotherapy, surgery, chemotherapy, and radiotherapy, may provide an effective and comprehensive anti-melanoma strategy.

show abstract

“…Calcium and DAG activate PKC, which, in turn, activates the MAPK and PI3K/AKT pathways allowing for the upregulation of cell proliferation and anti-apoptosis signals [21]. Additionally, activated PI3K/AKT pathway functions in tumor cell survival, epithelial mesenchymal transition (EMT), and angiogenesis.…”

Section: Melanoma Typesmentioning

confidence: 99%

Biology, Therapy and Implications of Tumor Exosomes in the Progression of Melanoma

Isola

Eddy

Chen

2016

Cancers

Self Cite

View full text Add to dashboard Cite

Cancer is the second leading cause of death in the United States, and about 6% of the estimated cancer diagnoses this year will be melanoma cases. Melanomas are derived from transformation of the pigment producing cells of the skin, melanocytes. Early stage melanoma is usually curable by surgical resection, but late stage or subsequent secondary metastatic tumors are treated with some success with chemotherapies, radiation and/or immunotherapies. Most cancer patients die from metastatic disease, which is especially the case in melanoma. A better understanding of tumor metastasis will provide insights and guide rational therapeutic designs. Recently, the importance of melanoma-derived exosomes in the progression of that cancer has become more apparent, namely, their role in various stages of metastasis, including the induction of migration, invasion, primary niche manipulation, immune modulation and pre-metastatic niche formation. This review focuses on the critical roles that melanoma exosomes play in the progression of this deadly disease.

show abstract

Metabotropic glutamate receptors in cancer

Cited by 82 publications

References 105 publications

Metabotropic glutamate receptors as a new therapeutic target for malignant gliomas

Metabotropic glutamate receptors as a new therapeutic target for malignant gliomas

Melanoma from Molecular Pathways to Clinical Treatment: An Up to Date Review

Biology, Therapy and Implications of Tumor Exosomes in the Progression of Melanoma

Contact Info

Product

Resources

About